Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase

Pages
2318–2323
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the possible related comorbidities.Keywords: Chitotriosidase, comorbidity, macrophage, psoriasis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Chitotriosidase (ChT) is an enzyme secreted by activated macrophages and neutrophils in response to proinflammatory signals.
📊
Key Findings & Data:This study aimed to investigate whether serum ChT activity increased in patients with psoriasis and related comorbidities.
💡
Conclusion & Impact:We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the possible related comorbidities.Keywords: Chitotriosidase, comorbidity, macrophage, psoriasis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Chitotriosidase (ChT) is an enzyme secreted by activated macrophages and neutrophils in response to proinflammatory signals. There is growing evidence indicating that ChT activity reflects the systemic inflammatory status. This study aimed to investigate whether serum ChT activity increased in patients with psoriasis and related comorbidities. Materials and methods: This cross-sectional study included 53 (28 with associated comorbidities and 25 without comorbidities) patients with psoriasis and 52 healthy volunteers. All participants underwent laboratory investigations for serum ChT levels, complete blood count, erythrocyte sedimentation rate, C-reactive protein, and serum lipid levels. Results: The patients with psoriasis showed significantly higher levels of ChT activity as compared to the healthy controls (23.5 ± 11.4 vs. 17.5 ± 10.4 μmol/mL/hour; p = 0.015). Additionally, the ChT activity was significantly higher in patients with comorbidities than in those without (p = 0.042). Conclusion: Our data support the pathogenetic role of inflammatory processes induced by macrophage activation in patients with psoriasis and related comorbidities. We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the possible related comorbidities.Keywords: Chitotriosidase, comorbidity, macrophage, psoriasis

🔖

Cite This Article

SÖZMEN, E. Y., İLANBEY, B., DEMİRBAŞ, A., ATASOY, M., GÜNAY, Ü., TÜRSEN, Ü., LOTTİ, T., ELMAS, Ö. F. (2022). A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2318–2323. https://ajindex.com/articles/609392

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015
  2. 386 (9997): 983-994. doi: 10.1016/S0140-6736(14)61909-7 2. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences 2019
  3. 20 (6):1475. doi: 10.3390/ijms20061475 3. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie AS et al. Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology 2017
  4. 76 (3):377-390. doi: 10.1016/j.jaad.2016.07.064 4. Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE et al. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. British Journal of Dermatology 2017
  5. 176 (3):650-658. doi: 10.1111/bjd.15021 5. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation 1994
  6. 93 (3):1288-1292. doi: 10.1172/JCI117084 6. van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. International Immunology 2005
  7. 17 (11):1505-1512. doi: 10.1093/intimm/dxh328 7. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. Journal of Biological Chemistry 1995
  8. 270 (44):26252-26256. doi: 10.1074/jbc.270.44.26252 8. Malaguarnera L. Chitotriosidase: the yin and yang. Cellular and Molecular Life Sciences 2006
  9. 63 (24):3018-3029. doi: 10.1007/s00018-006-6269-2 9. Turan E, Sozmen B, Eltutan M, Sozmen EY. Serum chitotriosidase enzyme activity is closely related to HbA1c levels and the complications in patients with diabetes mellitus type 2. Diabetes and Metabolic Syndrome 2017
  10. S503-S506. doi: 10.1016/j.dsx.2017.03.044 10. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respiratory Research 2020
  11. 21 (1):6. doi: 10.1186/s12931-019-1263-z 11. Yildiz BS, Barutcuoglu B, Alihanoglu YI, Alkan MB, Bilgin M et al. Serum chitotriosidase activity in acute coronary syndrome. Journal of Atherosclerosis and Thrombosis 2013
  12. 20 (2):134- 141. doi: 10.5551/jat.13920 12. Thein MS, Kohli A, Ram R, Ingaramo MC, Jain A et al. Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer. Cancer Biomarkers 2013
  13. 19 (4):383-391. doi: 10.5551/jat.139